Navigation Links
ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
Date:3/3/2009

Diagnostics and Therapeutics divisions.

2009 will be a pivotal year for ExonHit Therapeutics. Assuming successful clinical validation of EHT Dx21, its blood diagnostic test for Alzheimer's disease, the Company will put its first product on the market. Furthermore, assuming successful completion of the EHT 0202 Phase lla study, the Company will engage in out-licensing activities to support further development of this product in Alzheimer's disease.

2008 Consolidated financial results

Philippe Rousseau, Chief Financial Officer of ExonHit Therapeutics, said: "Our investment efforts in the clinical development of our lead compounds in both Diagnostics and Therapeutics will continue in the first half of 2009 whereas in the second part of the year, we are committed to invest in marketing to prepare for EHT Dx21's launch." He added: "Our financial situation remains healthy with more than 24 months of cash at the end of 2008 and a tool to strengthen our shareholder's equity, the warrant exercise period running until the end of June."

- Income Statement

Total revenues amount to EUR 4.2 million, a decrease of 22% compared to the EUR 5.4 million achieved in 2007. This decrease mainly comes from our Therapeutics activities as in 2007 we recognized a milestone payment in our strategic collaboration with Allergan in addition to the annual R&D payments.

Consolidated R&D revenues were EUR 4.2 million in 2008, down 21% compared to EUR 5.3 million in 2007. R&D revenues from grants decreased to EUR 0.01 million in 2008 from EUR 0.05 million in 2007.

R&D expenses have increased by 15% to EUR 9.9 million in 2008 compared to EUR 8.6 million in 2007, mainly as a result of increased expenses in clinical trials in both our therapeutics and diagnostics activities. In 2008, R&D revenues covered 43% of the Company's R&D expenses, as opposed to 62% in 200
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
2. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
3. Loic Maurel Joins Exonhit Therapeutics to Become CEO
4. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
5. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
6. ExonHit Appoints a New Management Board
7. ExonHit Therapeutics - 2007 Financial Results
8. ExonHit Builds A New Organisation
9. ExonHit and bioMerieux Amend Their Strategic Partnership
10. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
11. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... the 30-day review period following the filing of ... indications with the U.S. Food and Drug Administration ... active. Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, ... development of novel cancer immunotherapies, announced today that it ... Chief Executive Officer and William Ho , M.D., ... join an experienced management team led by veterans of ... , Ph.D., Chief Scientific Officer; Jay Powers , ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... high priority in the drug development approval process. Thus, innovator companies must understand ... Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational panels and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist ... Annual High Tech Awards. , Now in its 22nd year, this premier awards event ... here, across the nation and around the world. The OC Tech Alliance will announce ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... , , , 7.6.4 Long PCR , ... as desired with every temperature , command, enables a , ... , With Long PCR, this function can be used ... elongation. , , ...
... , , , , , ... set of conditions that can be applied to all PCR amplifications. For ... used, the annealing temperatures , of the PCRs can differ ... stringent annealing temperature is a prerequisite for reliable results , ...
... , , , , ... fragment using the PCR* are an everyday occurrence in the lab. For example, , ... which hinder, , or even prevent, further analyses (cycle ... of the PCR result. In such cases, PCR , ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3Using Gradient PCR to determine the optimum annealing temperature. 2
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... acetyl CoA carboxylase 2,or ACC2, appears to turn the ... in part why the animals can eat more and ... Medicine,researchers.,The report that appears online today in the Proceedings ... cells in these mice bred to lack ACC2," said ...
... University,of California, San Diego have invented a process ... of specialized cells being sought as possible,treatments for ... and Shu Chien, UCSD bioengineering professors, and Christopher,J. ... in a paper published in the February issue ...
... have discovered a way to overcome one of the ... kill normal cells in the,process of eradicating cancer cells.,In ... of the Proceedings of the,National Academy of Sciences (PNAS), ... into a specially designed,virus. The virus eradicated prostate cancer ...
Cached Biology News:Lack of enzyme turns fat cells into fat burners 2Priming embryonic stem cells to fulfill their promise 2Priming embryonic stem cells to fulfill their promise 3Columbia research lifts major hurdle to gene therapy for cancer 2
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
...
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... Angle Polypropylene Rotor designed for use ... CL3/CL3R** and Centra-MP4/MP4R*. A translucent lid ... ,EXCLUSIVE polypropylene rotor design provides excellent ... autoclaved. Polypropylene rotors are fully ...
Biology Products: